Table 3.

Statements With ≥80% Consensus Agreement but Generally Low-Quality Evidence

If BE is suspected on an endoscopic screening examination, the endoscopist should obtain multiple systematic biopsies from the suspected segment. (Agreement 92%, strongly agree 57%, agree 35%, neither 4%, disagree 4%).

If a patient who is fit for endoscopy is diagnosed with BE as documented by the presence of intestinal metaplasia on histology of biopsies obtained from the tubular esophagus, enrollment in a surveillance endoscopy program should be strongly considered. (Agreement 92%, strongly agree 35%, agree 57%, neither 8%).

Patients undergoing surveillance biopsies for BE should be on an adequate dose of proton pump inhibitors to control reflux symptoms and erosive esophagitis. (Agreement 91%, strongly agree 61%, agree 30%, neither 9%).

In patients with BE undergoing endoscopic therapy, endoscopic resection of more than two-thirds of the circumference is not generally recommended due to the risk of stricture. (Agreement 83%, strongly agree 13%, agree 70%, neither 17%).

Radiofrequency ablation is an acceptable treatment option for BE patients with flat mucosa containing HGD without any visible lesions confirmed by high-resolution, high-definition endoscopy. (Agreement 87%, strongly agree 35%, agree 52%, neither 13%).

In patients who have completed endoscopic eradication of HGD and/or T1a EAC, follow-up endoscopic surveillance should be performed at 3, 6, 12, 18, and 24 months and yearly thereafter. (Agreement 87%, strongly agree 26%, agree 61%, neither 13%).

In patients who have completed endoscopic eradication of HGD and/or T1a EAC, endoscopic surveillance should include targeted biopsies of any visible lesions along with random biopsies of the neosquamous mucosa. (Agreement 96%, strongly agree 52%, agree 44%, neither 4%).

Patients with EAC and no distant metastases on radiologic evaluation should undergo staging evaluation with endoscopic ultrasonography at the time of diagnosis (Agreement 87%, strongly agree 26%, agree 61%, neither 13%).

In patients with severe dysphagia from metastatic EAC, insertion of a self-expanding metal stent is the treatment of choice for symptom palliation. (Agreement 87%, strongly agree 26%, agree 61%, neither 13%).